The prevalence of lifestyle-related disorders such as obesity, diabetes, and hypertension, which may alter an individual’s immune response to allergens, is one factor. Additionally, advancements in diagnostic technologies like molecular diagnostics and biomarkers, development of cost-effective in vitro diagnostic tests, and growing lab automation have all contributed to the market growth.
Manufacturers are restructuring their drug development processes to meet global patient needs. These changes include the launch of new products like Dr. Reddy’s OTC eye allergy drop, Olopatadine Hydrochloride Ophthalmic Solution, and collaborative efforts like the one between Angany and Lincoln Diagnostics to improve allergy immunotherapy.
The market faces challenges like the high cost of diagnostic tests and treatments, lack of awareness about the severity of allergies, misdiagnosis, and stringent regulations for approval of new diagnostic technologies and therapeutic drugs. Side effects from certain treatments also pose challenges.
Notable advancements include a study by Stanford University’s Center for Allergy and Asthma Research indicating the potential of etokimab to desensitize individuals allergic to peanuts. HypoPet also announced the publication of crucial preclinical data for their cat allergy vaccine, HypoCat™, which targets the primary allergen.